Search
Make Good Use of Your Sidebar

Use this space for anything from simple blocks of text to powerful widgets, like our Twitter and Flickr widgets. Learn more.

To access Website Management, hit the 'esc' key or use this Login link.

Saturday
Jan122019

Musea's latest Exit

Guardant Health Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

October 9, 2018 at 4:03 PM EDT

REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH) today announced the closing of its initial public offering of 14,375,000 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase 1,875,000 additional shares of common stock, at a public offering price of $19.00 per share. The gross proceeds from the offering were approximately $273.1 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock were offered by Guardant Health. The shares commenced trading on The Nasdaq Global Select Market on October 4, 2018, under the ticker symbol “GH”.

J.P. Morgan Securities LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. Cowen and Company, LLC, Leerink Partners LLC and William Blair & Company, L.L.C. acted as co-managers for the offering.

Friday
Sep192008

MUSEA'S FIRST EXIT - AVANTOME

Musea’s first exit became official on July 23rd as Illumina, the biotech instrumentation giant, snapped up Avantome.  

http://www.tradingmarkets.com/.site/news/Stock%20News/1775391/ 

“Illumina said it will make a $25 million cash payment and contingent payments up to $35 million for the company. Avantome's principal founders, Mostafa Ronaghi and Helmy Eltoukhy, will join Illumina's management.”

Musea would like to congratulate Mostafa and Helmy on a job well done!

Wednesday
Mar052008

Musea invest in Avantome

Tabletop DNA sequencing